Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.
van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators. van den Berg MJ, et al. Among authors: steg pg. Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102. Eur Heart J. 2017. PMID: 28369481
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, Bhatt DL, Steg PG, Läll K, Mägi R, Gynnild MN, Ellekjær H, Saltvedt I, Tuñón J, Mahíllo I, Aceña Á, Kaminski K, Chlabicz M, Sawicka E, Tillman T, McEvoy JW, Di Angelantonio E, Graham I, De Bacquer D, Ray KK, Dorresteijn JAN, Visseren FLJ. Hageman SHJ, et al. Among authors: steg pg. Eur Heart J. 2022 May 7;43(18):1715-1727. doi: 10.1093/eurheartj/ehac056. Eur Heart J. 2022. PMID: 35165703 Free PMC article.
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL. Stone GW, et al. Among authors: steg pg. Eur Heart J. 2018 Dec 7;39(46):4112-4121. doi: 10.1093/eurheartj/ehy562. Eur Heart J. 2018. PMID: 30203006 Free PMC article. Clinical Trial.
Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.
Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ. Kaasenbrood L, et al. Among authors: steg pg. J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217. J Am Heart Assoc. 2018. PMID: 30369323 Free PMC article.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. Among authors: steg pg. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
1,187 results